Pharmacyclics (PCYC) will collaborate with a JNJ subsidiary to develop and commercialize an oral...

|By:, SA News Editor

Pharmacyclics (PCYC) will collaborate with a JNJ subsidiary to develop and commercialize an oral treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and multiple myeloma. But RBC Capital cuts its recommendation, noting near-term upside may be limited in 2012 given the vastly reduced probability that PCYC will be acquired. PCYC -8% premarket.